The abstract is read at the publisher; the summary is JClub's.
BNT166a (10–60 μg) was well tolerated in VACV-naive and VACV-experienced healthy adults, with mostly mild-to-moderate reactions and 100% binding seroresponse after dose 2.
- Why it matters: Mpox outbreaks create a need for scalable vaccines, and early human safety plus antibody responses are required to justify moving an mRNA candidate into later efficacy testing.
- What they did: In an open-label, non-randomised phase 1 dose-escalation trial (NCT05988203), healthy adults received two intramuscular BNT166a doses 4 weeks apart; solicited reactions were tracked through 7 days and adverse events through 28 days, with binding and neutralising antibodies followed to 12 months.
- The result: Local reactions occurred in 50–88% of VACV-naive participants after dose 1 and 60–93% after dose 2, and systemic events in 44–69% after dose 1 and 73–100% after dose 2; MPXV clade IIb neutralising antibodies were detected in 62–92% of VACV-naive groups and 93% of VACV-experienced participants, with titres waning toward baseline by 12 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.